Core Viewpoint - Real Bio Technology Co., Ltd. has submitted its Hong Kong IPO prospectus, which has now expired after six months, with China International Capital Corporation as its sole sponsor [1][2]. Company Overview - Real Bio is an innovative biotechnology company focused on the development, manufacturing, and commercialization of innovative drugs targeting viral infections, tumors, and cardiovascular diseases [2]. - The company's mission is to improve human health through genuine innovation, particularly in the fields of antiviral and antitumor therapies, addressing resistance issues in existing treatment options [2]. Research and Development Platforms - Real Bio has established a comprehensive R&D platform that includes: - A high-selectivity novel nucleoside broad-spectrum antitumor drug development platform - A TOPO1 inhibitor and XDC drug development platform - A drug target discovery and validation platform - An innovative drug design and optimization platform - These platforms cover the entire drug development process, from early target screening to preclinical research, clinical trials, and subsequent optimization, providing strong technical support and systematic assurance for accelerating the discovery and development of innovative drugs [2].